HPS-6 inhibitors belong to a specific chemical class characterized by their ability to modulate the activity of HPS-6, a molecular target with crucial implications in cellular processes. The term "HPS-6" refers to Hermansky-Pudlak syndrome 6, a protein associated with lysosome-related organelles and known for its role in intracellular trafficking. Inhibitors targeting HPS-6 operate at the molecular level, exerting their effects by interfering with the normal functioning of this protein. The HPS-6 inhibitors function through mechanisms that involve binding to specific sites on the protein, thereby altering its conformation or disrupting its interaction with other cellular components. This interference can have downstream effects on cellular processes, influencing the dynamics of organelles and vesicular transport within the cell.
HPS-6 inhibitors exhibit distinct chemical features that enable their selective binding to the target protein. These compounds often possess specific functional groups and spatial arrangements that facilitate interaction with the molecular architecture of HPS-6. The design and synthesis of HPS-6 inhibitors involve a comprehensive understanding of the structural and biochemical characteristics of the target protein, aiming to develop molecules with high affinity and specificity. Researchers in the field of molecular pharmacology and biochemistry are actively engaged in elucidating the precise modes of action of HPS-6 inhibitors, as well as optimizing their chemical structures to enhance efficacy and selectivity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine is known to raise the pH in the lysosome, which can disrupt its function and hence indirectly affect BLOC-2 activity. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Similar to chloroquine, hydroxychloroquine alters lysosomal pH and could disrupt processes dependent on BLOC-2. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
This compound is a specific inhibitor of V-ATPase, leading to lysosomal alkalinization and potentially affecting BLOC-2 function. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $65.00 $162.00 $650.00 $2550.00 | 109 | |
As a V-ATPase inhibitor, it can raise lysosomal pH, which may indirectly impact HPS-6's role in BLOC-2. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin disrupts lysosomal acidification, which could alter BLOC-2 mediated processes involving HPS-6. | ||||||
7-Methyladenine | 935-69-3 | sc-233690 | 100 mg | $173.00 | ||
This autophagy inhibitor can lead to the accumulation of autophagosomes, potentially affecting HPS-6 related pathways. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Another autophagy inhibitor that could influence lysosomal function and indirectly the activity of the BLOC-2 complex. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1 promotes the degradation of Vps34 PI3 kinase complexes, which are important for lysosomal biogenesis and function. | ||||||
U 18666A | 3039-71-2 | sc-203306 sc-203306A | 10 mg 50 mg | $140.00 $500.00 | 2 | |
This compound disrupts cholesterol trafficking and lysosomal storage, potentially impacting BLOC-2 function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can affect multiple signaling pathways, possibly influencing BLOC-2 activity. | ||||||